In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 0.82 below Nanobiotix S A average.

Within Major Pharmaceutical Preparations industry 338 other companies have achieved higher Quick Ratio than Nanobiotix S A in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 1768, from total ranking in the third quarter 2025 at 2013.

Explain Quick Ratio?
How much Cash & cash equivalents NBTX�s has?
What are NBTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NBTX/financial-strength

https://api.csimarket.com/api/v1/companies/NBTX/fundamentals

https://api.csimarket.com/api/v1/companies/NBTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

NBTX Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-13.37 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	20.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.82	Subscribe	Subscribe	Subscribe	Subscribe
NBTX's Total Ranking	# 1768	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	16.63 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	4.79 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 339
Healthcare Sector	# 618
Overall Market	# 1768

Quick Ratio Statistics
High	Average	Low
6.26	2.15	0.84
(Dec 31 2020)		(Dec 31 2024)

Financial Statements
Nanobiotix S A 's Current Liabilities	$ 75 Millions	Visit NBTX's Balance sheet
Nanobiotix S A 's Cash & cash equivalent	$ 62 Millions	Visit NBTX's Balance sheet
Source of NBTX's Sales		Visit NBTX's Sales by Geography

Cumulative Nanobiotix S A 's Quick Ratio

NBTX's Quick Ratio for the trailling 12 Months

NBTX Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-5.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	9.4 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.89	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1583	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-4.14 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	4.56 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to NBTX Financial Strength Comparisons >> Go to Compare NBTX Quick Ratio to its Competitors

News about Nanobiotix S a Quick Ratio

Nanobiotix Hits $20M Milestone Payment in Global Phase 3 Head and Neck Cancer Study

Nanobiotix, a leading biotechnology company specializing in physics-based approaches to revolutionize cancer treatment, has recently achieved a significant milestone in their ongoing global Phase 3 study. The study aims to evaluate the potential of NBTXR3, a first-in-class radioenhancer, in elderly patients suffering from head and neck cancer. As a result of successfully meeting the study s operational requirements, strategic partner Janssen Pharmaceutica NV, a subsidiary of Johnson and Johnson, has awarded Nanobiotix with a substantial $20M milestone payment.
Promising Advances in Cancer Treatment:
Nanobiotix, known for its groundbreaking nanomedicine technology, focuses on developing innovative solutions to enhance cancer therapies. NBTXR3, their lead product candidate, is designed to improve the effectiveness of radiation therapy by amplifying its localized effects and minimizing the damage caused to healthy tissues surrounding tumors.

On the trailing twelve months basis NBTX Cash & cash equivalent grew by 20.25 % in Q4 2025 year on year, while Current Liabilities increased to $75 millions, this led to increase in in Nanobiotix S A 's Quick Ratio to 0.89, Quick Ratio remained below NBTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 484 other companies have achieved higher Quick Ratio than Nanobiotix S A . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3631 to 4581.

Explain Quick Ratio?
How much Cash & cash equivalents NBTX�s has?
What are NBTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 485
Healthcare Sector	# 995
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.28	1.33	0.84
(Dec 31 2021)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Regeneron Pharmaceuticals Inc	2.26	$ 8,605.200 Millions	$ 3,815.400 Millions
Ultragenyx Pharmaceutical Inc	2.24	$ 680.000 Millions	$ 303.000 Millions
Corcept Therapeutics Inc	2.24	$ 372.152 Millions	$ 166.085 Millions
Petros Pharmaceuticals inc	2.24	$ 5.137 Millions	$ 2.293 Millions
Galectin Therapeutics Inc	2.22	$ 17.726 Millions	$ 7.967 Millions
Prf Technologies Ltd	2.22	$ 5.207 Millions	$ 2.348 Millions
Filana Therapeutics Inc	2.20	$ 95.502 Millions	$ 43.470 Millions
Mustang Bio inc	2.18	$ 17.266 Millions	$ 7.914 Millions
Dogwood Therapeutics inc	2.17	$ 6.525 Millions	$ 3.002 Millions
Omeros Corporation	2.17	$ 171.804 Millions	$ 79.208 Millions
Gossamer Bio Inc	2.16	$ 136.932 Millions	$ 63.435 Millions
Larimar Therapeutics Inc	2.11	$ 136.852 Millions	$ 64.795 Millions
Cue Biopharma Inc	2.09	$ 28.229 Millions	$ 13.494 Millions
Schrodinger Inc	2.09	$ 395.464 Millions	$ 189.136 Millions
Allarity Therapeutics Inc	2.09	$ 14.687 Millions	$ 7.030 Millions
Imunon Inc	2.08	$ 8.781 Millions	$ 4.217 Millions
Prelude Therapeutics Inc	2.05	$ 103.214 Millions	$ 50.250 Millions
Bridgebio Pharma Inc	2.04	$ 587.482 Millions	$ 287.971 Millions
Biomarin Pharmaceutical Inc	2.04	$ 1,560.609 Millions	$ 765.086 Millions
Scisparc Ltd	2.04	$ 4.591 Millions	$ 2.253 Millions
Travere Therapeutics Inc	2.02	$ 322.796 Millions	$ 159.904 Millions
Xoma Royalty Corporation	2.02	$ 82.908 Millions	$ 41.114 Millions
Ptc Therapeutics inc	2.00	$ 1,945.371 Millions	$ 973.104 Millions
Reviva Pharmaceuticals Holdings Inc	1.98	$ 14.439 Millions	$ 7.276 Millions
Alnylam Pharmaceuticals Inc	1.98	$ 2,908.484 Millions	$ 1,466.349 Millions
Atrium Therapeutics Inc	1.96	$ 382.517 Millions	$ 195.446 Millions
Azitra Inc	1.94	$ 2.068 Millions	$ 1.068 Millions
Pacira Biosciences inc	1.88	$ 238.424 Millions	$ 126.790 Millions
Verrica Pharmaceuticals Inc	1.83	$ 30.147 Millions	$ 16.437 Millions
Alx Oncology Holdings Inc	1.82	$ 44.790 Millions	$ 24.553 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.